Improvement in all domains of the female sexual function index (FSFI)1*

At 12 Weeks, Survey Results Demonstrated an Improvement in Total Score
of 62% with INTRAROSA vs Baseline1

At 12 Weeks, Survey Results Demonstrated the Following Improvements in Score from Baseline
  • Limitations: This post-hoc analysis of Study 2 data is not powered to show statistical significance. The study population did not have a diagnosis of sexual dysfunction. Further clinical studies are required to determine safety and efficacy of INTRAROSA for treatment of sexual dysfunction
*INTRAROSA is not indicated for the treatment of sexual dysfunction.2

At 12 Weeks, Survey Results Demonstrated an Improvement in Total Score of 62% with INTRAROSA vs Baseline1

At 12 Weeks, Survey Results Demonstrated the Following Improvements in Score from Baseline
  • Limitations: This post-hoc analysis of Study 2 data is not powered to show statistical significance. The study population did not have a diagnosis of sexual dysfunction. Further clinical studies are required to determine safety and efficacy of INTRAROSA for treatment of sexual dysfunction
*INTRAROSA is not indicated for the treatment of sexual dysfunction.2
Shield icon
See the INTRAROSA
safety profile
>
See More

Indication

INTRAROSA is a steroid indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.

Important Safety Information

INTRAROSA is contraindicated in women with undiagnosed abnormal genital bleeding.

Estrogen is a metabolite of prasterone. Use of exogenous estrogen is contraindicated in women with a known or suspected history of breast cancer. INTRAROSA has not been studied in women with a history of breast cancer.

In four 12-week randomized, placebo-controlled clinical trials, the most common adverse reaction with an incidence ≥2 percent was vaginal discharge. In one 52-week open-label clinical trial, the most common adverse reactions with an incidence ≥2 percent were vaginal discharge and abnormal Pap smear.

To report SUSPECTED ADVERSE REACTIONS, contact AMAG Pharmaceuticals at 1­-877-411-2510 or FDA at 1-800­-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information.

References: 1. Labrie F, Derogatis L, Archer DF, et al. Effect of intravaginal prasterone on sexual dysfunction in postmenopausal women with vulvovaginal atrophy. J Sex Med. 2015;12(12):2401‐2412. 2. Intrarosa® (prasterone) Prescribing Information. AMAG Pharmaceuticals, Inc; 2018.